Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Vascular surgeon accused of double murder pleads not guilty
The 39-year-old vascular surgeon allegedly killed his ex-wife and her husband on Dec. 30. If convicted, he faces the possibility of life in prison without parole.
IVL competition heats up as Boston Scientific enters US market
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?
Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.
Vascular surgeon indicted for murder of ex-wife and her husband
Michael McKee is accused of making the journey from Illinois to Ohio and then shooting the two victims in their home on Dec. 30. He was arrested after surveillance footage showed his car at the scene before and after the murders.
Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.

Vascular surgeon accused of double murder pleads not guilty

The 39-year-old vascular surgeon allegedly killed his ex-wife and her husband on Dec. 30. If convicted, he faces the possibility of life in prison without parole.

The Boston Scientific Seismiq intravascular lithotripsy (IVL) system entered commercial use in the U.S. in January 2026.

IVL competition heats up as Boston Scientific enters US market

Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.

Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?

Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.

Vascular surgeon indicted for murder of ex-wife and her husband

Michael McKee is accused of making the journey from Illinois to Ohio and then shooting the two victims in their home on Dec. 30. He was arrested after surveillance footage showed his car at the scene before and after the murders.

CGuard Prime carotid stent system was cleared by the U.S. Food and Drug Administration (FDA) in June 2025.

Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.

Hospital patient bays recovery Banner Health and Atlas Ambulatory Surgical Center (ASC) in Sun City, Arizona.

Office-based interventional labs see boost in pay in 2026

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

Boston Scientific to acquire Penumbra for $14.5B

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions.

Haemonetics acquires Irish medtech company focused on vessel closure for up to $215M

The device at the heart of this transaction is the PerQseal Elite system, a fully bioabsorbable patch for percutaneous vessel closure. The technology has already gained key approvals in Europe.